About kyverna therapeutics inc - KYTX
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
KYTX At a Glance
Kyverna Therapeutics, Inc.
5980 Horton Street
Emeryville, California 94608
| Phone | 1-510-925-2492 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -127,477,000.00 | |
| Sector | Health Technology | Employees | 112 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
KYTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.606 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.957 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.061 |
KYTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,138,187.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
KYTX Liquidity
| Current Ratio | 8.609 |
| Quick Ratio | 8.609 |
| Cash Ratio | 8.472 |
KYTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -66.792 |
| Return on Equity | -80.742 |
| Return on Total Capital | -46.384 |
| Return on Invested Capital | -78.153 |
KYTX Capital Structure
| Total Debt to Total Equity | 3.092 |
| Total Debt to Total Capital | 2.999 |
| Total Debt to Total Assets | 2.689 |
| Long-Term Debt to Equity | 1.614 |
| Long-Term Debt to Total Capital | 1.565 |